本文基于CheckMate 648临床试验的45个月随访数据，通过质量调整无症状和毒性生存期(Q-TWiST)分析方法，首次系统评估了纳武利尤单抗(NIVO)联合化疗(CHEMO)或联合伊匹木单抗(IPI)对比单纯化疗在晚期食管鳞状细胞癌(ESCC)患者中的风险-获益特征。研究证实两种联合方案均 ...

Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...

Opdivo is the first and only PD-1/L1 inhibitor to demonstrate superior first-line efficacy in upper GI cancers across histologies and tumor locations Statistically significant overall survival benefit ...

Bristol Myers Squibb (BMS) announced four-year follow-up results from the phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy ...

Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...

This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.